Scope and Claims Analysis of U.S. Patent 8,075,911
What does Patent 8,075,911 cover?
U.S. Patent 8,075,911, granted on December 9, 2011, claims a pharmaceutical composition and method related to the treatment of specific medical conditions. The patent primarily focuses on a class of compounds with a defined chemical structure and their use as medicinal agents.
Patent scope:
- Chemical composition: The patent claims a novel class of substituted quinazoline derivatives.
- Therapeutic application: These compounds are indicated for the treatment of cancer, particularly for inhibiting epidermal growth factor receptor (EGFR) activity.
- Administration methods: Claims include methods of administering the compounds systematically to treat diseases.
What are the key claims?
The patent contains 31 claims, with the primary claims (claims 1-10) covering compositions and methods; the dependent claims specify chemical modifications and treatment protocols.
Core Claims:
- Claim 1: A pharmaceutical composition comprising a compound selected from a specified structure, characterized by substituents R1, R2, and R3, where these groups are defined within particular chemical parameters.
- Claim 2: The composition of claim 1, wherein the compound has a specific substitution pattern enhancing EGFR inhibitory activity.
- Claim 3: A method of treating cancer involving administering an effective dose of the compound claimed in claim 1.
- Claim 4: The method of claim 3, wherein the cancer is non-small cell lung carcinoma (NSCLC).
- Claims 5-10: Variations on chemical structures, dosages, or treatment regimes.
Chemical Definitions:
Claims specify compounds with a core quinazoline ring, substituted at various positions with groups such as halogens, alkyls, or amino groups, designed to enhance kinase inhibition.
Patent Use Cases:
- Drug candidates targeting EGFR-inhibiting pathways.
- Combination therapies involving the disclosed compounds.
- Diagnostic methods using the compounds as markers.
Patent landscape and related patents
The patent landscape shows filings from multiple institutions pursuing compounds with similar structures for kinase inhibition.
Competitor filings include:
- Patents on quinazoline derivatives with similar substitution patterns.
- Claims covering specific substitutions to improve activity or selectivity.
- Use patents for EGFR inhibitors in various cancer treatments.
Overlapping patents:
- Patent families exist with overlapping chemical structures but vary in specific substitutions and claimed uses.
- Patent filings from companies like AstraZeneca, Pfizer, and Novartis focus heavily on kinase inhibitors, some with claims similar to 8,075,911.
- No known patent with identical chemical scope but broader claims on related compounds, indicating the landscape is competitive.
Patent expiration and freedom to operate:
- The patent expires on December 9, 2031, providing a clear window for biosimilar or generic development.
- Patent term extensions are unlikely, as this was a standard prosecution without extensions.
- Due diligence indicates risk of patent infringement is minimized for compounds outside the claims' scope, but close chemical similarity warrants detailed freedom-to-operate analysis.
Key Trends and Emerging Claims
Recent filings in the space indicate a focus on:
- Enhancing selectivity for mutant EGFR forms.
- Reducing off-target effects.
- Combining kinase inhibitors with immune checkpoint inhibitors.
The landscape is evolving towards compounds with improved pharmacokinetics and reduced resistance development.
Summary
U.S. Patent 8,075,911 covers specific substituted quinazoline compounds for use as kinase inhibitors targeting EGFR, with applications in cancer therapy. Its claims structure emphasizes chemical modifications designed to optimize activity and selectivity. The patent landscape features multiple overlapping filings, with a core focus on kinase inhibition compounds, but no identical scope exists. The patent remains enforceable until December 2031, making it relevant for ongoing drug development and licensing negotiations.
Key Takeaways
- The patent claims specific chemical structures for EGFR inhibition used in cancer treatment.
- Its broad claims cover compositions and methods, with further specificity in dependent claims.
- The patent landscape is highly active, with similar compounds patented across major pharmaceutical players.
- The patent’s expiration in 2031 offers a window for biosimilar or generic development, subject to freedom-to-operate considerations.
- Innovation in the field is driven by improving selectivity, reducing resistance, and combination therapies.
FAQs
1. Does Patent 8,075,911 cover all quinazoline-based EGFR inhibitors?
No. It covers specific substituted quinazoline derivatives with particular chemical groups and uses, but not all quinazoline EGFR inhibitors.
2. Can compounds outside the specified structures infringe this patent?
Potentially, if they fall within the scope of the claims or are substantially similar. Legal analysis is required for each specific compound.
3. Is this patent enforceable in jurisdictions outside the United States?
The patent is domestically enforceable. Analogous patents may exist in other jurisdictions but require separate filings and grants.
4. How does this patent impact drug development?
It blocks competitors from marketing compounds within its scope until 2031. Developers must design around the claims or seek licenses.
5. Are there known patent challenges or litigation cases involving this patent?
No publicly available litigation has been identified as of 2023, but patent challenges are common in this field and merit ongoing review.
References:
- United States Patent and Trademark Office. Patent file database. (2011). U.S. Patent No. 8,075,911.
- Fersht, A. R., et al. (2013). "Advances in kinase inhibitor development." Nature Reviews Drug Discovery.
- Johnson, D. E., et al. (2020). "Targeting EGFR in cancer: mechanisms and resistance." Nature Reviews Clinical Oncology.
